173 related articles for article (PubMed ID: 35086897)
1. Molecular Signature of
Alberge JB; Kraeber-Bodéré F; Jamet B; Touzeau C; Caillon H; Wuilleme S; Béné MC; Kampfenkel T; Sonneveld P; van Duin M; Avet-Loiseau H; Corre J; Magrangeas F; Carlier T; Bodet-Milin C; Chérel M; Moreau P; Minvielle S; Bailly C
J Nucl Med; 2022 Jul; 63(7):1008-1013. PubMed ID: 35086897
[TBL] [Abstract][Full Text] [Related]
2. Hybrid simultaneous whole-body 2-[
Jamet B; Carlier T; Bailly C; Bodet-Milin C; Monnet A; Frampas E; Touzeau C; Moreau P; Kraeber-Bodere F
Eur Radiol; 2023 Sep; 33(9):6438-6447. PubMed ID: 37022439
[TBL] [Abstract][Full Text] [Related]
3. Role of
Cavo M; Terpos E; Nanni C; Moreau P; Lentzsch S; Zweegman S; Hillengass J; Engelhardt M; Usmani SZ; Vesole DH; San-Miguel J; Kumar SK; Richardson PG; Mikhael JR; da Costa FL; Dimopoulos MA; Zingaretti C; Abildgaard N; Goldschmidt H; Orlowski RZ; Chng WJ; Einsele H; Lonial S; Barlogie B; Anderson KC; Rajkumar SV; Durie BGM; Zamagni E
Lancet Oncol; 2017 Apr; 18(4):e206-e217. PubMed ID: 28368259
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of [
Stolzenburg A; Lückerath K; Samnick S; Speer M; Kneer K; Schmid JS; Grigoleit GU; Hofmann S; Beer AJ; Bunjes D; Knop S; Buck AK; Einsele H; Lapa C
Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1694-1704. PubMed ID: 29610955
[TBL] [Abstract][Full Text] [Related]
5. Comparison of [
Stokke C; Nørgaard JN; Feiring Phillips H; Sherwani A; Nuruddin S; Connelly J; Schjesvold F; Revheim ME
Mol Imaging Biol; 2022 Oct; 24(5):842-851. PubMed ID: 35501622
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of
Han S; Woo S; Kim YI; Yoon DH; Ryu JS
Eur Radiol; 2021 Jan; 31(1):152-162. PubMed ID: 32809165
[TBL] [Abstract][Full Text] [Related]
7.
Morales-Lozano MI; Rodriguez-Otero P; Sancho L; Nuñez-Cordoba JM; Prieto E; Marcos-Jubilar M; Rosales JJ; Alfonso A; Guillen EF; San-Miguel J; Garcia-Velloso MJ
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077292
[TBL] [Abstract][Full Text] [Related]
8. Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma.
Jamet B; Zamagni E; Nanni C; Bailly C; Carlier T; Touzeau C; Michaud AV; Moreau P; Bodet-Milin C; Kraeber-Bodere F
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751375
[TBL] [Abstract][Full Text] [Related]
9. New Developments in Myeloma Treatment and Response Assessment.
Kraeber-Bodéré F; Jamet B; Bezzi D; Zamagni E; Moreau P; Nanni C
J Nucl Med; 2023 Sep; 64(9):1331-1343. PubMed ID: 37591548
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of Baseline
Moon SH; Choi WH; Yoo IR; Lee SJ; Paeng JC; Jeong SY; Lee SW; Kim K; Choi JY
Korean J Radiol; 2018; 19(3):481-488. PubMed ID: 29713226
[TBL] [Abstract][Full Text] [Related]
11. 11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma.
Chen M; Zhu W; Du J; Yang C; Han B; Zhou D; Huo L; Zhuang J
Sci Rep; 2021 Nov; 11(1):22188. PubMed ID: 34773054
[TBL] [Abstract][Full Text] [Related]
12. Standardization of
Zamagni E; Nanni C; Dozza L; Carlier T; Bailly C; Tacchetti P; Versari A; Chauvie S; Gallamini A; Gamberi B; Caillot D; Patriarca F; Macro M; Boccadoro M; Garderet L; Barbato S; Fanti S; Perrot A; Gay F; Sonneveld P; Karlin L; Cavo M; Bodet-Milin C; Moreau P; Kraeber-Bodéré F
J Clin Oncol; 2021 Jan; 39(2):116-125. PubMed ID: 33151787
[TBL] [Abstract][Full Text] [Related]
13. Low hexokinase-2 expression-associated false-negative
Abe Y; Ikeda S; Kitadate A; Narita K; Kobayashi H; Miura D; Takeuchi M; O'uchi E; O'uchi T; Matsue K
Eur J Nucl Med Mol Imaging; 2019 Jun; 46(6):1345-1350. PubMed ID: 30903198
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow segmentation and radiomics analysis of [
Milara E; Gómez-Grande A; Tomás-Soler S; Seiffert AP; Alonso R; Gómez EJ; Martínez-López J; Sánchez-González P
Comput Methods Programs Biomed; 2022 Oct; 225():107083. PubMed ID: 36044803
[TBL] [Abstract][Full Text] [Related]
15. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate.
Sachpekidis C; Mai EK; Goldschmidt H; Hillengass J; Hose D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
Clin Nucl Med; 2015 Jun; 40(6):e300-7. PubMed ID: 25783508
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment
Abe Y; Narita K; Kobayashi H; Kitadate A; Miura D; Takeuchi M; O'uchi E; O'uchi T; Matsue K
Eur J Nucl Med Mol Imaging; 2019 Jun; 46(6):1325-1333. PubMed ID: 30687892
[TBL] [Abstract][Full Text] [Related]
17.
Jung SH; Kwon SY; Min JJ; Bom HS; Ahn SY; Jung SY; Lee SS; Park MR; Yang DH; Ahn JS; Kim HJ; Lee JJ
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):107-115. PubMed ID: 30187105
[TBL] [Abstract][Full Text] [Related]
18. Whole-body (18)F-FDG PET identifies high-risk myeloma.
Durie BG; Waxman AD; D'Agnolo A; Williams CM
J Nucl Med; 2002 Nov; 43(11):1457-63. PubMed ID: 12411548
[TBL] [Abstract][Full Text] [Related]
19. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
20. Treatment response evaluation with
Sachpekidis C; Hillengass J; Goldschmidt H; Wagner B; Haberkorn U; Kopka K; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):50-62. PubMed ID: 27573638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
